Patients with type 2 diabetes mellitus display a typical atherogenic dyslipidemia marked by increased plasma triglycerides (TG) and VLDL-cholesterol concentrations and decreased HDL-cholesterol levels. Furthermore, hepatic steatosis, which is also strongly associated with cardiovascular disease risk ([@B1],[@B2]), is frequently observed in patients with type 2 diabetes mellitus ([@B3]--[@B5]).

We demonstrated previously that the HDL-raising effect of various classical lipid-lowering drugs was caused by a reduction in plasma cholesteryl ester transfer protein (CETP) that mediates the net transfer of cholesteryl esters from HDL to (V)LDL. In APOE\*3-Leiden.CETP mice, a well-established animal model for human-like lipoprotein metabolism, statins ([@B6]), fibrates ([@B7]), and niacin ([@B8]) decrease the hepatic lipid content (i.e., both TG and cholesterol), resulting in a decreased hepatic CETP expression accompanied by decreased plasma CETP levels and a consequently increased plasma HDL. Recently, we showed that a similar mechanism may account for the HDL-raising effect of pioglitazone in humans. In patients with type 2 diabetes mellitus, pioglitazone decreased hepatic TG content ([@B9]), accompanied by a decrease in plasma CETP concentration and increase in HDL level ([@B10]). In contrast, metformin did not affect either hepatic TG, plasma CETP, or HDL levels ([@B10]).

Lifestyle interventions such as diet-induced weight reduction and exercise are very important in the treatment of obese patients with type 2 diabetes mellitus. Recently, we reported that a 16-week very low calorie diet (VLCD) in obese patients with type 2 diabetes mellitus significantly decreased plasma total cholesterol and TG levels and markedly reduced hepatic TG content ([@B11]), but the potential beneficial effect of a VLCD on plasma CETP and HDL levels has not been studied. Therefore, using plasma samples from that study ([@B11]), we investigated whether prolonged caloric restriction reduces CETP concentration and thereby increases HDL levels in obese patients with type 2 diabetes mellitus.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Patients {#s6}
--------

The study protocol has been described in detail previously ([@B11]). Twenty-seven obese patients with insulin-dependent type 2 diabetes mellitus (14 men and 13 women) were included (mean ± SEM: age: 55 ± 2 years, BMI: 37.2 ± 0.9 kg/m^2^, HbA~1c~: 7.8 ± 0.2%). At baseline patients used 82 ± 11 units of insulin per day with or without concomitant use of metformin and/or sulfonyl ureum derivates. Exclusion criteria were as follows: smoking, unstable weight during 3 months before inclusion, or any other chronic disease. In an article published previously ([@B11]), we described only 12 out of the 27 patients from whom proton magnetic resonance spectroscopy (^1^H-MRS) scans could be obtained. The local ethics committee approved this protocol. All patients gave written informed consent, and the study was performed in accordance with the Declaration of Helsinki.

Study design {#s7}
------------

Patients were studied before the start and after completion of the 16-week VLCD. Three weeks before start of the VLCD all oral blood glucose--lowering medication was stopped and insulin therapy was intensified. The day before the start of the VLCD intervention, only short-acting insulin was prescribed. Patients did not use any blood glucose--lowering medication, including insulin, during the 16-week VLCD. The VLCD consisted of three liquid food shakes (Modifast Intensive; provided by Nutrition & Santé, Antwerp, Belgium) containing a total of 450 kcal/day and all essential micro- and macronutrients. Thirteen of the twenty-seven subjects simultaneously followed an exercise program in addition to the VLCD. Because exercise had no effect on outcome parameters ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0685/-/DC1)), data of all subjects were pooled for the present analyses.

Hepatic TG content {#s8}
------------------

Hepatic TG content was measured in supine position using ^1^H-MRS on a 1.5 Tesla whole-body MR scanner (Gyroscan ACS/NT15; Philips, Best, the Netherlands), exactly as described previously ([@B11]).

Plasma (apo)lipoprotein and CETP analyses {#s9}
-----------------------------------------

All plasma samples were obtained after an overnight fast before the start (i.e., after stopping all glucose-lowering medication including insulin) and after the 16-week VLCD protocol, stored in aliquots at −80°C, and analyzed after thawing once in a single laboratory (Leiden, the Netherlands). To ascertain that we could make adequate correlations, all analyses were performed within the same blood samples in the same assay runs. Plasma cholesterol and TG concentrations were determined using enzymatic kits (no. 236691 and 11488872, respectively; Roche Molecular Biochemicals, Indianapolis, IN). Plasma phospholipids were determined using the phospholipids B kit (Wako Chemicals, Neuss, Germany). Plasma CETP concentration was quantified using kit CETP ELISA Daiichi (Daiichi Pure Chemicals, Tokyo, Japan). HDL fractions were obtained after precipitation of apolipoprotein (apo)B-lipoproteins from 50 μL plasma by adding 25 μL 36% polyethylene glycol 6000 (PEG6000, no.81260; Sigma Aldrich) The HDL-cholesterol and phospholipids were determined as described above. Plasma apoAI and apoB100 levels were determined with the Human ApoAI ELISA kit (no. 3710--^1^H; Mabtech AB, Nacka, Sweden) and Human ApoB ELISA kit (no. 3715--^1^H; Mabtech AB), respectively.

Cholesterol efflux study {#s10}
------------------------

Cholesterol efflux to total plasma and apoB-depleted human plasma were determined using the human monocyte cell line THP-1 as cholesterol donor. THP-1 cells were obtained from European Collection of Cell Cultures and maintained in medium A (RPMI 1640 with 25 mmol/L HEPES buffer, supplemented with 10% fetal bovine serum, 1% [l]{.smallcaps}-glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin) at 37°C in 5% CO~2~. Before the experiment, THP-1 cells were seeded into 24-well plates at density of 5 × 10^5^ cells per well and differentiated into macrophages with 0.1 μmol/L phorbol 12-myristate-13-acetate (no. P1585; Sigma Aldrich) within 3 days. Macrophages were washed three times with PBS and incubated in medium B (RPMI 1640 with 25 mmol/L HEPES buffer, supplemented with 2% fetal bovine serum, 1% [l]{.smallcaps}-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin, 50 μg/mL acetyl-LDL, and 10 μCi/mL \[1α,2α(n)-^3^H\]-cholesterol (no. NET139001MC; Perkin Elmer, the Netherlands) for 1 day at 37°C in 5% CO~2~. After incubation, cells were washed three times with PBS and the efflux assay was started by adding total human plasma or apoB-depleted human plasma diluted to 1% in medium C (RPMI 1640 with 25 mmol/L HEPES buffer, supplemented with 1% [l]{.smallcaps}-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin, and 0.5 mg/mL BSA). The whole assay was carried out in triplicate. To be able to normalize results between series of experiments and to correct for plate-to-plate variation, efflux to a standard preparation of HDL (50 μg protein/mL) was determined in triplicate. After 4-h incubation, medium was collected and centrifuged. Subsequently, \[^3^H\]cholesterol was quantified by liquid scintillation counting. Total cellular ^3^H-cholesterol was determined after extraction of the cells with 0.1 mol/L NaOH. Cholesterol efflux rate was calculated by dividing the ^3^H activity in the medium by the sum of the ^3^H activity in the medium and the cell extract. Background values (the efflux in the absence of plasma) were subtracted.

Statistics {#s11}
----------

Data are expressed as means ± SEM. Paired *t* tests were used for the statistical comparisons between measurements at baseline and after 16 weeks of caloric restriction. For correlation analysis, Pearson correlation analysis was used. A *P* value \< 0.05 was considered statistically significant.

RESULTS {#s12}
=======

In line with our previous observations in 12 patients ([@B11]), a subset of the 27 patients who were included in the current study, the VLCD profoundly reduced bodyweight from 113.1 ± 3.7 to 87.7 ± 2.9 kg (*P* \< 0.05) and decreased BMI from 37.2 ± 0.9 to 28.9 ± 0.8 kg/m^2^ (*P* \< 0.05). In addition, in the 12 patients from whom ^1^H-MRS scans could be obtained, hepatic TG content reduced considerably from 21.2 ± 4.2 to 3.0 ± 0.9% (*n* = 12; *P* \< 0.001) as reported previously ([@B11]).

Plasma CETP and (apo)lipoproteins {#s13}
---------------------------------

When compared with baseline, VLCD decreased plasma CETP concentration (−18.2%; *P* \< 0.01). In addition, VLCD reduced plasma levels of total cholesterol (−13.1%; *P* \< 0.001), TG (−45.1%; *P* \< 0.001), phospholipid (−15.2%; *P* \< 0.0001), LDL-cholesterol (−15.8%; *P* \< 0.01), and apoB100 (−13.9%; *P* \< 0.01). VLCD did not alter plasma HDL-cholesterol and HDL-phospholipids, but increased apoAI (+16.2%; *P* \< 0.05) ([Table 1](#T1){ref-type="table"}). The change in body weight after 16 weeks of VLCD did not correlate with the change in either plasma TG (*R*^2^ = 0.0000; *P* = 0.9952), total cholesterol (*R*^2^ = 0.0471; *P* = 0.2769), phospholipid (*R*^2^ = 0.0305; *P* = 0.3837), LDL-cholesterol (*R*^2^ = 0.0320; *P* = 0.3717), HDL-cholesterol (*R*^2^ = 0.0086; *P* = 0.6460), or HDL-phospholipid (*R*^2^ = 0.0013; *P* = 0.8570).

###### 

Plasma CETP and (apo)lipoprotein levels in obese patients with type 2 diabetes mellitus and hepatic steatosis in response to 16 weeks of VLCD

  Plasma parameters            Baseline      After VLCD    Δ (%)   *P* value
  ---------------------------- ------------- ------------- ------- -----------
  CETP (μg/mL)                 2.48 ± 0.15   2.03 ± 0.14   −18.2   0.0021
  Total cholesterol (mmol/L)   5.76 ± 0.30   5.00 ± 0.22   −13.1   0.0007
  Triglycerides (mmol/L)       2.41 ± 0.28   1.32 ± 0.10   −45.1   0.0003
  Phospholipids (mmol/L)       2.69 ± 0.11   2.28 ± 0.07   −15.2   0.0000
  LDL-cholesterol (mmol/L)     3.99 ± 0.27   3.36 ± 0.20   −15.8   0.0028
  ApoB100 (mg/dL)              130 ± 6       111 ± 5       −13.9   0.0016
  HDL-cholesterol (mmol/L)     0.84 ± 0.04   0.91 ± 0.06   ---     NS
  HDL-phospholipids (mmol/L)   0.98 ± 0.03   0.98 ± 0.05   ---     NS
  ApoAI (mg/dL)                135 ± 10      156 ± 11      +16.2   0.0174

Data are presented as means ± SEM (*n* = 27). Δ values are calculated by comparing values obtained after VLCD with those obtained at baseline from obese patients with type 2 diabetes mellitus. *P* values are calculated using paired Student *t* test. NS, not significant.

Cholesterol efflux {#s14}
------------------

VLCD decreased cholesterol efflux from THP-1 cells to total plasma obtained from patients compared with plasma from baseline (−14.5%; *P* \< 0.001; [Fig. 1*A*](#F1){ref-type="fig"}). Similarly, the capacity of apoB-depleted plasma obtained after VLCD to promote cholesterol efflux was lower than that of apoB-depleted plasma obtained at baseline (−14.9%; *P* \< 0.001; [Fig. 1*B*](#F1){ref-type="fig"}).

![Cholesterol efflux to total plasma and apoB-depleted plasma. THP-1 cells were loaded with \[^3^H\]cholesterol and incubated for 4 h at 37°C with total plasma (1% vol/vol; *A*) or apoB-depleted plasma (1% vol/vol; *B*), obtained before and after VLCD from 27 obese patients with type 2 diabetes mellitus. Cholesterol efflux rate is calculated by dividing ^3^H-activity in the medium by the sum of the ^3^H-radioactivity in the medium and cell extract. Data are means ± SEM. *P* values are calculated using paired Student *t* test. \**\*\*P \<* 0.001 as compared with baseline.](2576fig1){#F1}

Correlation analysis showed that cholesterol efflux to total plasma positively correlated with plasma total cholesterol (*R*^2^ = 0.2416; *P* \< 0.001) and plasma total phospholipid (*R*^2^ = 0.3499; *P* \< 0.001). Cholesterol efflux to total plasma positively correlated with non-HDL-cholesterol (*R*^2^ = 0.2339; *P* \< 0.001) and non-HDL-phospholipid (*R*^2^ = 0.2855; *P* \< 0.001) rather than HDL-cholesterol or HDL-phospholipid (both *P* \> 0.05; [Supplementary Fig. 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0685/-/DC1)). Moreover, no significant correlation was observed between cholesterol efflux to plasma and apoAI ([Supplementary Fig. 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0685/-/DC1)).

CONCLUSIONS {#s15}
===========

A main finding from the current study is that prolonged caloric restriction by a 16-week VLCD in obese patients with type 2 diabetes mellitus and hepatic steatosis, which considerably reduces hepatic TG content (−85%) ([@B11]), also markedly decreases plasma CETP concentration (−18.2%). This observation corroborates our recent finding that a reduction of the hepatic lipid content (−30.5%), as induced by pioglitazone, also associates with a reduction in plasma CETP concentration (−11.6%) in patients with type 2 diabetes mellitus ([@B10]). However, the potency of prolonged caloric restriction to reduce hepatic lipid content and plasma CETP concentration exceeds that of pioglitazone treatment considerably.

These data are in full accordance with our previous observations that lowering hepatic lipids (i.e., TG as well as cholesterol) in APOE\*3-Leiden.CETP mice by classical lipid-lowering drugs decreased hepatic CETP mRNA expression, resulting in decreased plasma CETP concentration ([@B6]--[@B8]). Because CETP expression is regulated by liver X receptor α (LXRα) for which oxysterols are natural ligands ([@B12]) and the liver cholesterol level determines LXRα activation ([@B13]), we concluded from those studies that a decrease in hepatic cholesterol content, associated with a decrease in cholesterol derivatives, reduces hepatic LXRα activation, thereby downregulating CETP mRNA transcription. Although it is unknown whether hepatic TG levels reflect levels of hepatic cholesterol and oxysterols in the current study, since we cannot assess hepatic (oxy)sterols noninvasively in humans, hepatic TG and cholesterol levels were highly correlated (*r* = 0.867) in 33 Chinese subjects (Dr. P. Parini, personal communication). Therefore, it is likely that the reduction in plasma CETP concentration induced by VLCD also reduces hepatic LXRα-activated CETP mRNA transcription, thereby reducing plasma CETP. Our data corroborate those of Laimer et al. ([@B14]) who showed that substantial weight loss in morbidly obese women induced by laparoscopic gastric banding surgery also decreased plasma CETP mass (−8.3%) at 1 year after surgery.

The effect of caloric restriction on HDL levels is still under debate. Although a single study reported that an average of 6 years of caloric restriction in 18 subjects increased HDL-cholesterol ([@B15]), other studies demonstrated that both 6 months and 2 years of caloric restriction in eight subjects in fact decreased plasma HDL-cholesterol ([@B16],[@B17]). Moreover, caloric restriction had conflicting effects on HDL-cholesterol among different diet groups even in one study: HDL-cholesterol was either increased or unaffected ([@B18]). The current study is the first to show that caloric restriction by a VLCD increased the plasma level of the main HDL protein constituent apoAI (+16.2%), which is supposed to be a good (negative) predictor of cardiovascular disease risk ([@B19]). However, the VLCD did not increase HDL-cholesterol levels. Our previous studies in mice ([@B6]--[@B8]) and in patients with type 2 diabetes mellitus ([@B10]) showed that reduction of hepatic lipids and plasma CETP, as induced by drugs, were in fact related to increased plasma HDL-cholesterol levels. In fact, treatment of only 20 patients with type 2 diabetes mellitus with pioglitazone resulted in a significant increase in HDL-cholesterol despite less pronounced decreases in hepatic lipid and plasma CETP ([@B10]), suggesting that our present study including 27 patients would not be underpowered to detect a potential effect on HDL-cholesterol. It is known that the LXRα target ATP binding cassette A1 (ABCA1) plays a crucial role in HDL maturation by mediating the lipidation of plasma apoAI ([@B20]). Furthermore, hepatic ABCA1 is the main contributor to the loading of HDL with cholesterol as evidenced by studies in mice that selectively lack ABCA1 from the liver ([@B21]). Collectively, it is thus conceivable that the dramatic reduction in hepatic lipids largely downregulates the hepatic expression of ABCA1, resulting in reduced lipidation of plasma apoAI with liver-derived cholesterol, thereby counteracting the expected rise in HDL-cholesterol as a result of the reduction in CETP.

The reduced ratio of HDL-cholesterol over apoAI as induced by VLCD may be expected to result in an increased ability of total plasma and apoB-depleted plasma to induce cholesterol efflux from cholesterol-laden macrophages. However, we observed that the VLCD actually reduced the capacity of total plasma and apoB-depleted plasma to induce cholesterol efflux from THP-1 cells, even after discarding the three subjects showing the largest decrease in cholesterol efflux from the analysis. Correlation analysis revealed that HDL constituents (cholesterol, phospholipid, and apoAI) did not correlate with cholesterol efflux to plasma. Instead, the decrease in cholesterol efflux to plasma was mainly related to the decrease in total phospholipid levels in plasma. Collectively, these data indicate that the total lipoprotein surface area in plasma, rather than the HDL level, determines the capacity of plasma to induce cholesterol efflux.

Our findings are in line with those of a recent study showing that the cholesterol efflux capacity of plasma was independent of total HDL-cholesterol or apoAI levels ([@B22]). In fact, independently of HDL-cholesterol, sera with high efflux capacity had a significant increase in ABCA1-mediated efflux as a result of the presence of preβ-1 HDL. Likewise, another study showed that, although both pioglitazone and statins increase HDL-cholesterol, pioglitazone but not statins increases the cholesterol efflux capacity of plasma, and no correlation was noted between the change in HDL-cholesterol and the change in cholesterol efflux capacity ([@B23]). Overall, the cholesterol efflux capacity of plasma is thus not simply related to HDL-cholesterol or apoAI, although the capacity of HDL to mediate cholesterol efflux from macrophages has recently been established to strongly inversely associate with carotid intima-media thickness and likelihood of angiographic coronary artery disease ([@B23]). The fact that we were unable to detect a correlation between cholesterol efflux and HDL-cholesterol or apoAI thus probably indicates that VLCD does not improve the functionality of HDL with respect to mediating cholesterol efflux.

A limitation of the current study may be the small study group. Although we initially included 27 patients for the VLCD intervention, hepatic TG quantification by MRS was possible in only 12 patients, mainly related to limitations for maximum weight and circumference of the MRI scanner. Second, the design of the current human study does not permit to assess causal relationships between hepatic lipid content and plasma CETP or apoAI level. Nonetheless, the results are in accordance with data obtained from mechanistic studies in a mouse model relevant for human lipoprotein metabolism ([@B6]--[@B8]).

In conclusion, this study indicates that prolonged caloric restriction, which considerably reduces hepatic TG content, also markedly decreases plasma CETP concentration. This is in full accordance with our previous findings in APOE\*3-Leiden.CETP mice, in which we showed that classical lipid-lowering drugs concurrently lowered hepatic lipids resulting in decreased plasma CETP concentration. Furthermore, the VLCD increased plasma apoAI levels without improving functionality of HDL with respect to cholesterol efflux from macrophages.
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